Der er ialt indberettet cerebrovaskulære bivirkninger hos 1, 3% af de aripiprazol- behandlede patienter i forsøgene sammenlignet med 0, 6% af de placebo- behandlede.
Overall, 1.3% of aripiprazole-treated patients reported cerebrovascular adverse events compared with 0.6% of placebo-treated patients in these trials.